Medicure (MPH) Q2 2026 earnings summary

Executive summary

• Net revenue for the quarter ended June 30, 2026 was $7.4 million, up from $6.7 million year-over-year.

• Net loss increased to $1.4 million ($0.14/share) from $786,000 ($0.08/share) year-over-year, mainly due to a $864,000 CMS liability and higher non-cash amortization expenses.

• Adjusted EBITDA improved to $172,000 from negative $28,000 year-over-year, driven by pharmacy segment growth and ZYPITAMAG sales.

Financial highlights

• Gross profit for the quarter was $3.2 million, down from $3.4 million year-over-year.

• Cost of goods sold rose to $4.2 million from $3.2 million year-over-year.

• Research and development expenses were $608,000, down from $741,000 year-over-year.

• Unrestricted cash at June 30, 2026 was $1.8 million, down from $3.8 million at December 31, 2025.

Outlook and guidance

• Marley Drug aims to grow ZYPITAMAG sales and expand exclusive product offerings and partnerships.

• Continued investment in clinical development, including a Phase 3 trial for MC-1 targeting PNPO deficiency.